Our Challenges Don’t Define Us.
Our Actions Do.

The Choroideremia Research Foundation (CRF) is the largest organization in the world focused on the search for a cure for choroideremia (CHM). Our mission is to raise funds in support of scientific research leading to a treatment or cure of choroideremia, a hereditary retinal-degenerative disease that causes blindness; to educate people affected by the disease; and to inform the public.

Founded in 2000, a small group of individuals affect with CHM formed the CRF to make a difference for themselves, their families and the many others living this disease. There are an estimated 6,600 affected male CHMers in the United States.

Our Achievements and History

CRF has funded over $4.5 million in research on the causes and potential cures for choroideremia since being granted nonprofit status in 2000.

The organization hosts regular conferences for patients and families as well as scientific symposia for researchers and clinicians. It also offers one-day regional meetings several times a year around the world. Webinars and interactive online chats are offered (and recorded) several times monthly on topics such as emotional support, research, assistive technology, clinical trials and genetic testing.

In August 2021, the CRF spearheaded the launch of the International Choroideremia Research Network (ICRN), a global alliance of researchers from around the world who are working in concert to accelerate scientific knowledge about CHM. The network is composed of over 90 multi-disciplinary vision professionals with varied experiences, backgrounds, and interests from 25 countries.

CRF hosts a CHM patient registry.  The organization legislatively advocates for patients nationally and internationally, provides education for medical professionals, and offers information and one-on-one support to patients and family members.

CRF was conceived by a small group of patients in 1999. It formally established nonprofit status in 2000 and began funding research in 2002. A few of CRF’s first early research projects included establishment of a CHM mouse model, creating induced pluripotent stem cell (iPSC) models, formation of a human CHM cell biobank, and support of several pre-clinical gene therapy research studies which ultimately led to launch of three clinical trials.

CRF is now exploring collaborations and/or funding development of a CHM pig model, possible pharmaceutical therapies, gene therapy, optogenetics (light sensing), neuroprotection (to delay progression), RNA and DNA editing, stem cell therapy, sight replacement therapies, transplantation, assistive/bionic technologies, and understanding genetics and phenotypes (characteristics and variations) of CHM cells and how these differences may affect progression and outcomes.

Directors

Naama Goldman-Einhorn, PhD
Tel-Aviv, Israel – Clinical psychologist

Bob Hillier
Ontario, Canada – Retired hydrogeologist, a founding board member of the CRF

Michael Laengsfeld
Friedberg/Hessen, Germany – CEO at DVBS, VP at Commerzbank AG

Jason McKinney, MBA
Gilmer, Texas – Former restauranteur & City Councilman in Colfax, CA, a founding board member of the CRF

John Oster
Rochester, New York – Owner and President of Edgemere Development, a founding board member of the CRF

Dan Peterson
Trimont, Minnesota – Owner of Daniel Peterson Construction Company

Tracey Pretorius
Kirkland, Washington – Senior Director, Global Security Research Strategy at Microsoft

Angela Ricketts
St. Louis, Missouri – Co-Founder and Director of Better Life Maids

John-Ross Rizzo, MD
New York, New York – Associate Professor, NYU Langone Medical Center, Dept. of Rehabilitation Medicine and Dept of Neurology

Craig Rowley
Jay, Maine – Workforce Management Analyst at WEX, Inc

Jon Salois
Worcester, Massachusetts – VP of Sales for Atlas Distributing

Our Science Advisory Board

Tomas Aleman, MD | Professional webpage
Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Kapil Bharti, PhD | Professional webpage
Senior Investigator, Ocular and Stem Cell Translational Research Unit, National Eye Institute, National Institutes of Health, Intramural Research Program
Bethesda, Massachusetts

Jacque Duncan, MD | Professional webpage
Professor in Ophthalmology, University of California San Francisco
San Francisco, California

Rachel Huckfeldt, MD, PhD | Professional webpage
Associate Surgeon and Director, Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear; Assistant Professor of Ophthalmology, Harvard Medical School
Boston, Massachusetts

Alex Iannaccone, MD, MS, FARVO | Professional webpage
Director, Center for Retinal Degenerations and Ophthalmic Genetic Diseases, and Professor, Ophthalmology, Duke University Department of Ophthalmology
Durham, North Carolina

Maureen McCall, PhD | Professional webpage
Professor & Vice Chair for Research, Department of Ophthalmology & Visual Sciences, School of Medicine, University of Louisville
Louisville, Kentucky

Chris Moen, MD | Professional webpage
Chief Medical Officer, Choroideremia Research Foundation; Medical Director, NaviHealth
Wilmington, Delaware

Mark Pennesi, MD, PhD | Professional webpage
Division Chief, Ophthalmic Genetics, Professor of Ophthalmology, School of Medicine, Oregon Health and Science University (OHSU) Casey Eye Institute
Portland, Oregon

Jess Thompson, MD, MS | Professional webpage
Chair, Science Advisory Board, Choroideremia Research Foundation; Cardiothoracic Surgeon, Yavapai Cardiac Surgery
Prescott, Arizona

Stephen Tsang, MD, PhD | Professional webpage
Professor of Ophthalmology and Professor of Pathology and Cell Biology, Columbia University Department of Pathology and Cell Biology
New York, New York

Ajoy Vincent, MBBS, MS | Professional webpage
Staff Ophthalmologist, Ophthalmology and Vision Sciences; Medical Director, Visual Electrophysiology Unit; Associate Scientist Genetics and Genome Biology Research Institute, The Hospital for Sick Children
Toronto, Ontario, Canada

Michael Young, PhD, FARVO | Professional webpage
Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute; Director, Minda de Gunzburg Center for Retinal Regeneration, Harvard Medical School; Associate Scientist, Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, Massachusetts